Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670046 · ClinicalTrials.gov registry record · Phase 2
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00670046 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 15 participants.
The verdict
NCT00670046, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well valproic acid works in treating patients with progressive, non-metastatic prostate cancer.
Interventions
- DRUG valproic acid
- OTHER standard of care follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670046
The ClinicalTrials.gov registry entry for NCT00670046 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valproic acid is the first listed.
NCT00670046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670046 about?
NCT00670046 is a clinical study titled "Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer". RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well va...
What is the current status of trial NCT00670046?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00670046?
The interventions under investigation include: valproic acid (DRUG), standard of care follow-up (OTHER).
Who is sponsoring clinical trial NCT00670046?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.